Synergistic antitumour effect of TNF-SAM2 with melphalan and doxorubicin in isolated limb perfusion in rats

Anticancer Research

Volumn 20, Issue 5 B, 2000, Pages 3491-3496

  De Wilt, J H W ^a   Soma, G I ^a   Ten Hagen, T L M ^a   Kanou, J ^a   Takagi, K ^a   Nooijen, P T G A ^a   Seynhaevel, A L B ^a   Eggermont, A M M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; MELPHALAN; MUTANT PROTEIN; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; DRUG RESPONSE; HISTOPATHOLOGY; LIMB PERFUSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SARCOMA;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DIVISION; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; HINDLIMB; MALE; MELPHALAN; NEOPLASM TRANSPLANTATION; RATS; RATS, INBRED BN; SARCOMA, EXPERIMENTAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033635640     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Treatment of melanoma in-transit metastases confined to the limb
2. High-dose recombinant tumor necrosis factor alnha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma
3. Regional therapy of melanoma
4. Isolated limb perfusion with high-dose tumor necrosis factor-α in combination with interferon-γ and melphalan for nonresectable extremity soft tissue sarcomas: A multicenter trial
5. Isolated Limb Perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas: The cumulative multicenter european experience
6. Limb salvage by isolated limb perfusion (ILP) with TNF and melphalan in patients with locally advanced soft tissue sarcomas: Outcome of 270 ILPs in 246 patients
7. Synergistic antitumour effect of recombinant human tumour necrosis factora with melphalan in isolated limb perfusion in the rat
8. Isolated limb perfusion with TNFa and melphalan in a rat osteosarcoma: A new anti-tumour approach
9. Synergistic antitumour effects of TNF-α and melphalan in an isolated limb perfusion model of rat sarcoma: A histopathologic, immunohistochemical and electron microscopic study
10. Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats
11. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion
12. TNF augments intratumoral concentrations of doxorubicin in TNF-based isolated limb perfusion in rat sarcoma models and enhances antitumour effects
13. Phase I study of recombinant tumor necrosis factor in cancer patients
14. Use of tumor necrosis factor in isolated hepatic perfusion
15. Isolated hepatic perfusion in the pig with TNF-a with and without melphalan
16. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver
17. Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan and mitomycin C using ballooncatheter techniques: A pharmacokinetic study in pigs
18. Isolated lung perfusion with tumor necrosis factor: A swine model in preperation of human trials
19. In vivo isolated kidney perfusion with TNF-a in tumour bearing rats
20. Improvement of cytotoxicity of tumor necrosis factor (TNF) by increase in basicity of its N-terminal region
21. Biological activities of novel recombinant tumor necrosis factor having N-terminal amino acid sequences derived from cytotoxic factors produced by THP-1 cells
22. Human TNF mutants with selective activity on the p55 receptor
23. Human tumor necrosis factor α (TNFα) mutants with exclusive specificity for the 55-kDa or 75-kDa TNF receptors
24. Novel muteins of human tumor necrosis factor with potent antitumor activity and less lethal toxicity in mice
25. Novel mutein of tumor necrosis factor (F4614) with reduced hypotensive effect
26. Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency
27. Generation of a mouse tumor necrosis factor mutant with antiperitonitis and desensitization activity comparable to those of the wild type but with reduced systemic toxicity
28. Antitumor activity of tumor necrosis factor a conjugated with divinyl ether and maleic anhydride copolymer on solid tumors in mice
29. Antitumor effect of systemic administration of novel recombinant tumor necrosis factor (rTNF-S) with less toxicity than conventional rTNF-α in vivo
30. Serum-free in vitro bioassay for the detection of tumor necrosis factor
31. Hemodynamic evaluation of recombinant human tumor necrosis factor (TNF)-α, TNF-SAM2 and liposomal TNF-SAM2 in an anesthezed dog model
32. Formulation and antitumor efficacy of liposomal-caprylated-TNF-SAM2
33. Hyperthermic isolated limb perfusion (HILP) with tumor necrosis factor alpha (TNF) alone for metastaic inransit melanoma
34. VWF release and platelet aggregation in human melanoma after perfusion with TNFα
35. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNFα)
36. Assessment of the role of neutrophils on the antitumor effect of TNFα in an in vivo isolated limb perfusion model in sarcoma-bearing brown norway rats
37. Comparitive in vitro studies of the potentiation of tumor necrosis factor (TNF)-α, TNF-α, and TNF-SAM2 cytotoxicity by hyperthermia
38. Cytotoxic interactions of tumor necrosis factor, melphalan and 41.8°C hyperthermia
39. Tumor necrosis factor alpha augments tumor effects in isolated hepatic perfusion with melphalan in a rat sarcoma model
40. Low dose tumor necrosis factor-α augments antitumour activity of Stealth liposomal doxorubicin (Doxil) in soft tissue sarcoma-bearing rats